Do you want to read an article? Please log in or register.
Neoadjuvant Intralesional Daromun (L19IL2/L19TNF) in Resectable Locally Advanced Melanoma: An Update on the Efficacy and Safety Results of the PIVOTAL Phase III Trial
Skin Cancer
Related content
Gastrointestinal Cancer
Neoadjuvant Chemotherapy With CAPOX Versus Chemoradiation for Locally Advanced Rectal Cancer With Uninvolved Mesorectal Fascia (CONVERT): Final Results of a Phase III Trial
J Clin Oncol
Mei WJ, Wang XZ, Zhang X, Sun YM, Yang CK, Lin JZ, Wu ZG, Zhang R, Wang W, Li Y, Zhuang YZ, Lei J, Wan XB, Ren YK, Cheng Y, Li WL, Wang ZQ, Xu DB, Mo XW, Ju HX, Ye SW, Zhao JL, Zhang H, Gao YH, Zeng ZF, Xiao WW, Zhang XP, Li YF, Xie E, Feng YF, Tang JH, Wu XJ, Chen G, Li LR, Lu ZH, Wan DS, Bei JX, Pan ZZ, Yu JH, Ding PR
doi: 10.1200/JCO-25-00731
RECOMMENDED
Breast Cancer
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer: Updated Efficacy Results from the phase 3 EMBER-3 trial
★ 2
Recommended by
Prof. Dr Beat Thürlimann, Faculty Member
Ann Oncol
Jhaveri KL, Neven P, Casalnuovo ML, Kim SB, Tokunaga E, Aftimos P, Saura C, O'Shaughnessy J, Harbeck N, Carey LA, Curigliano G, Watanabe J, Lim E, Huang J, Qingyuan Z, Llombart-Cussac A, Huang C, Desai B, Limay Y, Wang XA, Cao S, Bidard FC
doi: 10.1016/j.annonc.2025.11.018
Genitourinary Cancer
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial
Ann Oncol
Choueiri TK, Albigès L, McDermott DF, Hammers HJ, Escudier B, Burotto M, Plimack ER, Porta C, George S, Powles T, Donskov F, Atkins MB, Gurney H, Kollmannsberger CK, Grimm MO, Barrios C, Castellano D, Grünwald V, Tomita Y, Rini BI, Jiang R, van Kooten Losio M, Lee CW, Tannir NM, Motzer RJ
doi: 10.1016/j.annonc.2026.02.017
Lung, Respiratory and Thoracic Cancer
Efficacy and safety of subcutaneous and intravenous administration of atezolizumab in patients with non-small cell lung cancer, including early-stage, locally advanced or metastatic disease: Updated results of the IMscin001 and IMscin002 randomized studies
Lung Cancer
Burotto M, Zvirbule Z, Alvarez R, Chewaskulyong B, Felip E, Majem M, Korbenfeld E, Kolb-Sielecki J, Isla D, Barata T, Bustillos A, Herraez-Baranda LA, Tosti N, Young F, Zanghi J, Cappuzzo F
doi: 10.1016/j.lungcan.2026.109452
Lung, Respiratory and Thoracic Cancer
Sex-specific efficacy and safety outcomes in patients with resectable stage III non-small-cell lung cancer (NSCLC) undergoing neoadjuvant therapies: a pooled analysis of the SAKK trials 16/96, 16/00, 16/01, 16/08 and 16/14
ESMO Open
Frehner L, Schär S, Hayoz S, Guckenberger M, Finazzi T, Mark M, Addeo A, Mauti LA, Betticher D, Stupp R, Curioni-Fontecedro A, Peters S, Früh M, Rothschild SI, Pless M, König D, Opitz I, Ris HB, Özdemir BC, Schmid S
doi: 10.1016/j.esmoop.2025.105870
Non-Malignant Blood Disorders
Efficacy and Safety of Subcutaneous Efgartigimod PH20 in Adults With Primary Immune Thrombocytopenia (ADVANCE SC): A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 3 Trial
Am J Hematol
Cooper N, Broome CM, Miyakawa Y, McDonald V, Al-Samkari H, Khelif A, Cataland SR, Barcellini W, Yang R, Mei H, Matthijssens F, Hultberg A, Ciurlia G, Gandini D, Ayguasanosa J, De Beuf K, Pastouret S, Ghanima W, Rodeghiero F, Bussel JB, ADVANCE SC Investigator Trial Group
doi: 10.1002/ajh.70303
Sarcoma
Brigimadlin Versus Doxorubicin in Advanced Dedifferentiated Liposarcoma: Efficacy, Safety and Translational Data from Brightline-1, a Randomized Phase 2/3 Trial
Clin Cancer Res
Schöffski P, Sanfilippo R, Martín-Broto J, Kawai A, Desai J, LoRusso P, Maki RG, Jones RL, Blay JY, Smrke A, Abdul Razak A, Italiano A, Sebio A, Bahleda R, Lee YC, van der Graaf WTA, Zhang X, Biyukov T, Teufel M, Fu E, Lahmar M, Wagner AJ
doi: 10.1158/1078-0432.CCR-26-0509
Non-Malignant Blood Disorders
Efficacy and Safety of Marstacimab Prophylaxis in Hemophilia A/B With Inhibitors: Results from the Phase 3 BASIS Trial
Blood
Matino D, Acharya S, Taylor CT, Sun P, Agathon D, Raje S, Gould T, Palladino A, Mahlangu J
doi: 10.1182/blood.2025031065
Breast Cancer
Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the randomized phase III trial HER2CLIMB-02
Ann Oncol
Hurvitz SA, Loi S, O'Shaughnessy J, Okines AFC, Tolaney SM, Sohn J, Saura C, Zhu X, Cameron D, Bachelot T, Hamilton E, Curigliano G, Wolff AC, Harbeck N, Masuda N, Vahdat L, Zaman K, Valdes-Albini F, Block M, Pluard T, Tan TJ, Gawryletz C, Chan A, Bedard PL, Yerushalmi R, Xu B, Schmitt M, Xie D, Borges VF, HER2CLIMB-02 study investigators
doi: 10.1016/j.annonc.2025.11.005